Pharma sector stocks today, July 29: J.B. Chemicals falls 3.73%, Divis Laboratories gains 1.84%, Glenmark Pharma up 1.43%
NiveshIQ
NSE: IPCALAB · Pharma
Ipca Laboratories Ltd.
₹1,774.50▼ ₹14.50 (-0.81%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on IPCALAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Ipca Laboratories Ltd.
Ipca Laboratories Limited is a leading integrated pharmaceutical company with a strong presence in India and globally. The company's core business revolves around manufacturing and marketing formulations and active pharmaceutical ingredients (APIs) across various therapeutic segments. Its key revenue drivers include APIs in anti-hypertensive, anti-malarial, and diuretic therapeutic areas, as well as generic and branded formulations in multiple therapeutic segments. Recent developments suggest a mixed market sentiment with analysts holding a 'Hold' view and mixed signals. Despite this, the company has shown resilience with a 2.87% surge in stock price for three consecutive sessions. With a revenue of ₹9506 Cr and net income of ₹910 Cr, Ipca Laboratories Limited presents a stable growth outl
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹7,705 Cr +24.20% | ₹8,940 Cr +16.00% | ₹9,646 Cr +7.90% |
| EBITDA Margin | 17.16% | 19.31% | 22.32% |
| Net Profit | ₹522.00 Cr +9.00% | ₹785.00 Cr +50.40% | ₹1,184 Cr +50.80% |
| EPS | ₹21.58 | ₹29.08 | ₹44.98 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Pharma sector stocks today, July 29: J.B. Chemicals falls 3.73%, Divis Laboratories gains 1.84%, Glenmark Pharma up 1.43%
Ipca Laboratories: మార్కెట్ క్యాప్ ₹48,000 కోట్లకు చేరిక - ఇన్వెస్టర్లకు శుభవార్త!
🔒
+ 3 more stories about Ipca Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹2, 388 Cr, PAT ₹307 Cr, EPS ₹11.79, EBITDA margin 24.2%. Growth context: revenue QoQ -0.1%, PAT QoQ -15.7%. Street verdict: inline, revenue surprise -0.5%, PAT surprise -2.8%.
Management commentary highlights the company's focus on product launches, approvals, and therapy-mix improvement as key ...
FY26 (last completed FY): revenue ₹9, 646 Cr, PAT ₹1, 184 Cr, EBITDA margin 22.3%, EPS ₹44.98. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for IPCALAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track IPCALAB alongside your other holdings
Unlock full IPCALAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Ipca Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Ipca Laboratories Ltd. (IPCALAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Ipca Laboratories Ltd.?
Ipca Laboratories Ltd. operates in the Pharma sector with a market capitalisation of ₹4,625,789.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.